BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Silva P, de Almeida M, Silva J, Albino S, Espírito-Santo R, Lima M, Villarreal C, Moura R, Santos V. (E)-2-Cyano-3-(1H-Indol-3-yl)-N-Phenylacrylamide, a Hybrid Compound Derived from Indomethacin and Paracetamol: Design, Synthesis and Evaluation of the Anti-Inflammatory Potential. Int J Mol Sci 2020;21:E2591. [PMID: 32276463 DOI: 10.3390/ijms21072591] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 da Silva PR, do Espírito Santo RF, Melo CO, Pachú Cavalcante FE, Costa TB, Barbosa YV, E Silva YMSM, de Sousa NF, Villarreal CF, de Moura RO, Dos Santos VL. The Compound (E)-2-Cyano-N,3-diphenylacrylamide (JMPR-01): A Potential Drug for Treatment of Inflammatory Diseases. Pharmaceutics 2022;14:188. [PMID: 35057082 DOI: 10.3390/pharmaceutics14010188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Bodnar RJ. Endogenous opiates and behavior: 2020. Peptides 2022. [DOI: 10.1016/j.peptides.2022.170752] [Reference Citation Analysis]
3 Bian M, Ma QQ, Wu Y, Du HH, Guo-Hua G. Small molecule compounds with good anti-inflammatory activity reported in the literature from 01/2009 to 05/2021: a review. J Enzyme Inhib Med Chem 2021;36:2139-59. [PMID: 34628990 DOI: 10.1080/14756366.2021.1984903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]